Cargando…

Diagnostic Efficacy and Safety of Gadoxetate Disodium vs Gadobenate Dimeglumine in Patients With Known or Suspected Focal Liver Lesions: Results of a Clinical Phase III Study

PURPOSE: The aim of this study is to evaluate the diagnostic efficacy and safety of gadoxetate disodium vs gadobenate dimeglumine in patients with known or suspected focal liver lesions. METHODS: This was a prospective, multicenter, double-blind, randomized, inter-individual Phase III study. The pri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zech, Christoph J, Schwenke, Carsten, Endrikat, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379790/ https://www.ncbi.nlm.nih.gov/pubmed/30799932 http://dx.doi.org/10.1177/1178623X19827976

Ejemplares similares

The Unusual Suspect: Gadobenate-Dimeglumine Induced Kounis Syndrome
por: Choudhry, Faiza, et al.
Publicado: (2019)

Safety profile of gadoxetate disodium in elderly patients (≥65 years)
por: Endrikat, Jan, et al.
Publicado: (2017)

Severe Adverse Drug Reaction to Gadobenate Dimeglumine
por: Singer, Benjamin D., et al.
Publicado: (2009)

Comparison of Gadopentetate dimeglumine and Gadobenate dimeglumine in depiction of non-ischemic fibrosis in hypertrophic cardiomyopathy
por: Rudolph, Andre, et al.
Publicado: (2009)

Single dose gadobenate dimeglumine for imaging chronic of myocardial infarction in comparison to double dose gadopentetate dimeglumine
por: Bauner, Kerstin U, et al.
Publicado: (2009)

Low-dose gadobenate dimeglumine-enhanced MRI of the kidney for the differential diagnosis of localized renal lesions
por: Schneider, Guenther, et al.
Publicado: (2015)

(18) F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine
por: Kirchner, Julian, et al.
Publicado: (2017)

Small Brain Lesion Enhancement and Gadolinium Deposition in the Rat Brain: Comparison Between Gadopiclenol and Gadobenate Dimeglumine
por: Violas, Xavier, et al.
Publicado: (2022)

Gadoxetic Acid (Gd-EOB-DTPA)-Enhanced MRI versus Gadobenate Dimeglumine (Gd-BOPTA)-Enhanced MRI for Preoperatively Detecting Hepatocellular Carcinoma: an Initial Experience
por: Park, Yulri, et al.
Publicado: (2010)

Nebulized liposomal gadobenate dimeglumine contrast formulation for magnetic resonance imaging of larynx and trachea
por: Wei, Xiaohui, et al.
Publicado: (2011)

Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients
por: Endrikat, Jan, et al.
Publicado: (2015)

A Comparison between Gadofosveset Trisodium and Gadobenate Dimeglumine for Steady State MRA of the Thoracic Vasculature
por: Camren, G. Paul, et al.
Publicado: (2014)

MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine
por: Brismar, Torkel B., et al.
Publicado: (2011)

Gadobenate dimeglumine (MultiHance) or gadoterat emeglumine (Dotarem) for brain tumour imaging? An intra-individual comparison
por: Vaneckova, M, et al.
Publicado: (2015)

Gadobenate Dimeglumine as an Intrabiliary Contrast Agent: Comparison with Mangafodipir Trisodium with Respect to Non-dilated Biliary Tree Depiction
por: Lim, Joon Seok, et al.
Publicado: (2005)

Myocardial T1 mapping and determination of partition coefficients at 3 tesla: comparison between gadobenate dimeglumine and gadofosveset trisodium
por: Nacif, Marcelo Souto, et al.
Publicado: (2018)

Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis
por: Li, Xiu-Mei, et al.
Publicado: (2017)

Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma
por: Li, Yueming, et al.
Publicado: (2021)

Hypointense Hepatic Lesions Depicted on Gadobenate Dimeglumine-Enhanced Three-Hour Delayed Hepatobiliary-Phase MR Imaging: Differentiation between Benignancy and Malignancy
por: Hwang, Hye Sun, et al.
Publicado: (2009)

Single-Dose Gadobutrol in Comparison With Single-Dose Gadobenate Dimeglumine for Magnetic Resonance Imaging of Chronic Myocardial Infarction at 3 T
por: Wildgruber, Moritz, et al.
Publicado: (2014)

Use of oral gadobenate dimeglumine to visualise the oesophagus during magnetic resonance angiography in patients with atrial fibrillation prior to catheter ablation
por: Faletti, Riccardo, et al.
Publicado: (2014)

Dose‐Lowering in Contrast‐Enhanced MRI of the Central Nervous System: A Retrospective, Parallel‐Group Comparison Using Gadobenate Dimeglumine
por: DeLano, Mark C., et al.
Publicado: (2021)

Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis?
por: Kirchin, M A, et al.
Publicado: (2015)

Safety and Efficacy of Gadoxetate Disodium–Enhanced Liver MRI in Pediatric Patients Aged >2 Months to <18 Years—Results of a Retrospective, Multicenter Study
por: Geller, James, et al.
Publicado: (2016)

Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver
por: Huh, Jimi, et al.
Publicado: (2015)

Does gadoxetate disodium affect MRE measurements in the delayed hepatobiliary phase?
por: Plaikner, M., et al.
Publicado: (2018)

Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T
por: Besa, Cecilia, et al.
Publicado: (2015)

Imaging Findings of Hepatic Ewing’s Sarcoma on Computed Tomography and Gadobenate Dimeglumine-enhanced Magnetic Resonance Imaging: A Case Report and Literature Review
por: Lu, Tao, et al.
Publicado: (2022)

Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers
por: Lochrin, Sarah E., et al.
Publicado: (2021)

Preoperative radiomics model using gadobenate dimeglumine-enhanced magnetic resonance imaging for predicting β-catenin mutation in patients with hepatocellular carcinoma: A retrospective study
por: Zeng, Fengxia, et al.
Publicado: (2022)

Gadoxetate Disodium enhanced spectral dual-energy CT for evaluation of cholangiocarcinoma: Preliminary data
por: Thomas, John V., et al.
Publicado: (2016)

Analysis of the Performance of Gadoxetic Acid Disodium MRI in Predicting Microvascular Invasion of Hepatocellular Carcinoma
por: Chen, Jiao, et al.
Publicado: (2022)

Intrahepatic diffuse periportal enhancement patterns on hepatobiliary phase gadoxetate disodium-enhanced liver MR images: Do they correspond to periportal hyperintense patterns on T2-weighted images?
por: Onishi, Hiromitsu, et al.
Publicado: (2019)

Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC
por: Cannella, Roberto, et al.
Publicado: (2022)

Breast lesion detection and characterization with contrast‐enhanced magnetic resonance imaging: Prospective randomized intraindividual comparison of gadoterate meglumine (0.15 mmol/kg) and gadobenate dimeglumine (0.075 mmol/kg) at 3T
por: Clauser, Paola, et al.
Publicado: (2018)

Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging for the Detection of Hepatocellular Carcinoma: A Meta-Analysis
por: Liu, Xijiao, et al.
Publicado: (2013)

Shrunken Hepatic Hemangioma Following Delineated Peritumoral Hyperintensity on Gadoxetic Acid Disodium-enhanced MR Imaging
por: Haradome, Hiroki, et al.
Publicado: (2017)

Influence of age on gadoxetic acid disodium-induced transient respiratory motion artifacts in pediatric liver MRI
por: Hojreh, Azadeh, et al.
Publicado: (2022)

Predicting microvascular invasion in hepatocellular carcinoma: A dual‐institution study on gadoxetate disodium‐enhanced MRI
por: Jiang, Hanyu, et al.
Publicado: (2022)

Predicting histologic differentiation of solitary hepatocellular carcinoma up to 5 cm on gadoxetate disodium-enhanced MRI
por: Yang, Ting, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uo5faiki3fmsv406sug089qsnj